Subsequently, the PALOMA-2 (2) and PALOMA-3 (6) phase III clinical trials showed a significant increase in PFS with the addition of palbociclib to either letrozole or fulvestrant in first- or second-line treatment of advanced ER+ breast cancer, respectively. The gene discussed is ESR1; the disease is breast carcinoma.